Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Genmab A/S (GMXAY)

Genmab A/S (GMXAY)
18.3500 +0.1600 (+0.88%) 07/17/19 [OTC US]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Wed, Jul 17th, 2019
Day Low
18.2300
Day High
18.3500
Open 18.2401
Previous Close 18.1900 18.1900
Volume 13,100 13,100
Avg Vol 23,635 23,635
Stochastic %K 47.66% 47.66%
Weighted Alpha +9.71 +9.71
5-Day Change +0.2600 (+1.44%) +0.2600 (+1.44%)
52-Week Range 12.1000 - 19.0000 12.1000 - 19.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 207.45
  • Price/Book 12.90
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.4650 +5.07%
on 06/27/19
Period Open: 17.9200
19.0000 -3.42%
on 07/08/19
+0.4300 (+2.40%)
since 06/17/19
3-Month
16.3300 +12.37%
on 05/13/19
Period Open: 16.9400
19.0000 -3.42%
on 07/08/19
+1.4100 (+8.32%)
since 04/17/19
52-Week
12.1000 +51.65%
on 10/25/18
Period Open: 17.5000
19.0000 -3.42%
on 07/08/19
+0.8500 (+4.86%)
since 07/17/18

Business Summary

Genmab A/S, incorporated on June 11, 1998, is a biotechnology company that utilizes antibody products. The Company's first marketed antibody, ofatumumab (Arzerra), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 18.4300
1st Resistance Point 18.3900
Last Price 18.3500
1st Support Level 18.2700
2nd Support Level 18.1900
3rd Support Level N/A

See More

52-Week High 19.0000
Last Price 18.3500
Fibonacci 61.8% 16.3642
Fibonacci 50% 15.5500
Fibonacci 38.2% 14.7358
52-Week Low 12.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades